All In Biotech

Drug Trial Radar · NCT06778265

An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease

An Exploratory Clinical Study to Evaluate UX-DA001 Injection (Human Midbrain Dopaminergic Progenitor Cells Injection) in Subjects With Idiopathic Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Ruijin Hospital
First posted
Jan 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease. UX-DA001 manufactured from participant's own cells will differentiate into mature dopaminergic neurons after being transplanted into the brain of the participant.

Conditions

  • Parkinson Disease, Idiopathic

Interventions

  • UX-DA001Biological

    UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery. Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and and severity of adverse events (AEs) associated with surgery and/or investigational productTime frame: within 4 weeks post surgery
  2. The incidence and severity of AEs/serious adverse events (SAEs)Time frame: From baseline to 2 years post surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.